AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 27492881
Drug: Regional anaesthesia
RxNorm normalized name: ACL6SP45 REGIONAL ANESTHESIA KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regional anaesthesia (brachial plexus block [BPB] with 0.5% L-bupivacaine and 1.5% lidocaine with epinephrine)
Trial: 27492881
Drug: Local anaesthesia
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anaesthesia (0.5% L-bupivacaine and 1% lidocaine injected subcutaneously)
Trial: 27493790
Drug: Tofacitinib 5
RxNorm normalized name: tofacitinib 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofacitinib 5 mg two times a day
Trial: 27493790
Drug: Tofacitinib 10
RxNorm normalized name: tofacitinib 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofacitinib 10 mg two times a day
Trial: 27494163
Drug: RIX4414 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RIX4414 vaccine (2 doses, liquid formulation, separated by ≥4 weeks)
Trial: 27494911
Drug: Decolonization therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decolonization therapy with oral aminoglycosides (gentamicin and neomycin/streptomycin)
Trial: 27494911
Drug: Gentamicin oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin oral therapy
Trial: 27494911
Drug: Neomycin/streptomycin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neomycin/streptomycin therapy
Trial: 27495287
Drug: Oral sodium
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral sodium bicarbonate (0.3, 0.6 and 1.0 mEq/kg/day) for 6 weeks
Trial: 27496946
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D deficiency (25-OHD <25 nmol/l)
Trial: 27496946
Drug: Normal vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal vitamin D levels (25-OHD >75 nmol/l)
Trial: 27497862
Drug: CTX-DP (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CTX-DP (2 million, 5 million, 10 million, or 20 million cells by stereotactic ipsilateral putamen injection)
Trial: 27499222
Drug: Pre-procedural unfractioned
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-procedural unfractioned heparin
Trial: 27499222
Drug: Pre-procedural 600mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-procedural 600mg clopidogrel loading dose
Trial: 27499694
Drug: E/E' ratio
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E/E' ratio goal-directed therapy in kidney recipients with baseline diastolic dysfunction
Trial: 27499979
Drug: NIR thoracoscope
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NIR thoracoscope with indocyanine green (ICG) at a dosage of 0.2 mg/kg
Trial: 27499979
Drug: NIR thoracoscope
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NIR thoracoscope with indocyanine green (ICG) at a dosage of 0.6 mg/kg
Trial: 27502708
Drug: Alisertib 50
RxNorm normalized name: Alisertib
DrugBank: Alisertib (DB05220)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alisertib 50 mg PO b.i.d. d1-d7 every 21 days
Trial: 27502928
Drug: Azithromycin or
RxNorm normalized name: azithromycin Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin or Doxycycline (exact dosage and duration not specified)
Trial: 27502928
Drug: Self-collection of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-collection of anorectal and vaginal swabs before treatment and at weeks 1, 2, 4, 6, 8, 10, and 12
Trial: 27503642
Drug: Ceftazidime-avibactam (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftazidime-avibactam (single 2-h intravenous infusion); cohort 1: 2,000 to 500 mg; cohort 2: 2,000 to 500 mg [≥40 kg] or 50 to 12.5 mg/kg [<40 kg]; cohorts 3 and 4: 50 to 12.5 mg/kg
Trial: 27504630
Drug: IgM-enriched immunoglobulin
RxNorm normalized name: IgM-enriched immunoglobulins
DrugBank: Pentaglobin (DB15865)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IgM-enriched immunoglobulin (IgM-IVIg) (5 mg/kg/d over three days)
Trial: 27506223
Drug: Smartphone application
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smartphone application for insulin titration
Trial: 27506432
Drug: Abdominoperineal excision
RxNorm normalized name: pNF1-Blast Excised
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abdominoperineal excision (APE) for rectal cancer
Trial: 27507113
Drug: Hypochloremia (chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypochloremia (chloride ≤96 mmol/L)
Trial: 27507877
Drug: Selinexor (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selinexor (30 mg/m²) in combination with fludarabine and cytarabine
Trial: 27510535
Drug: Fish-oil therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish-oil therapy
Trial: 27512620
Drug: Ester-C(®) (EC,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ester-C(®) (EC, 1000 mg vitamin C)
Trial: 27512620
Drug: Placebo (PL,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (PL, 0 mg vitamin C)
Trial: 27512620
Drug: Ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic acid (AA, 1000 mg vitamin C)
Trial: 27514314
Drug: Ultra-hypofractionated radiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultra-hypofractionated radiation treatment
Trial: 27514463
Drug: Statin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin therapy guided by pharmacogenetic testing
Trial: 27514463
Drug: Standard statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard statin therapy without pharmacogenetic guidance
Trial: 27515248
Drug: Low-dose humanized
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose humanized anti-CD20 antibody, veltuzumab
Trial: 27515250
Drug: Imatinib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib plus steroids as induction
Trial: 27515250
Drug: Imatinib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib plus chemotherapy during consolidation
Trial: 27516088
Drug: Salmeterol/Fluticasone combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol/Fluticasone combination (SFC)
Trial: 27520989
Drug: ivabradine 5
RxNorm normalized name: ivabradine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ivabradine 5 mg twice daily (adjusted to 7.5 mg twice daily if HR >60 bpm)
Trial: 27521361
Drug: Cessation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cessation of injection drug use
Trial: 27521361
Drug: Former injection
RxNorm normalized name: Triple Wormer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Former injection drug users who are HCV aviremic
Trial: 27525031
Drug: Modified Atkins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified Atkins diet (20 to 40 g of carbohydrates daily)
Trial: 27525046
Drug: Dietary treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary treatment with extensively hydrolyzed casein formula containing Lactobacillus rhamnosus GG (group 2)
Trial: 27525190
Drug: T3D-959 (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T3D-959 (1.0 mg/kg/day)
Trial: 27525540
Drug: Exenatide QW
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exenatide QW 2 mg
Trial: 27526051
Drug: Conventional medical,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional medical, laser, or surgical treatment
Trial: 27528114
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment course for CRPC patients
Trial: 27528724
Drug: AM0010 (Pegylated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AM0010 (Pegylated Recombinant Human Interleukin-10) at doses of 1 to 40 μg/kg once per day, self-administered subcutaneously.
Trial: 27530528
Drug: Quarterly postal
RxNorm normalized name: Quarter Mate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quarterly postal and online antibiotic prescription feedback over 24 months
Trial: 27531679
Drug: Daratumumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daratumumab plus lenalidomide (25 mg/day orally on days 1-21 of each cycle) and dexamethasone (40 mg/week)
Trial: 27532019
Drug: Vemurafenib (VEM)
RxNorm normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vemurafenib (VEM) 960 mg twice daily for 6 weeks followed by Ipilimumab (IPI) 10 mg/kg every 3 weeks for 4 doses (induction), then every 12 weeks (maintenance) until disease progression or unacceptable toxicity
Trial: 27532019
Drug: Vemurafenib (VEM)
RxNorm normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vemurafenib (VEM) at previously tolerated dose after progression on IPI
Trial: 27532363
Drug: HHHFNC at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HHHFNC at 4 to 6 L/min
Trial: 27532364
Drug: Exemestane (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exemestane (25 mg oral daily) plus Everolimus (10 mg oral daily)
Trial: 27532364
Drug: Exemestane (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exemestane (25 mg oral daily) plus Placebo
Trial: 27534260
Drug: Correlation with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Correlation with serum insulin concentrations
Trial: 27535544
Drug: Daily assessments
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily assessments and long-term follow-up
Trial: 27535663
Drug: Plerixafor 240
RxNorm normalized name: Plerixafor
DrugBank: Plerixafor (DB06809)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Plerixafor 240 μg/kg administered subcutaneously every other day from day +2 until day +21 or until neutrophil recovery
Trial: 27535748
Drug: Evofosfamide (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evofosfamide (120 mg/m2 to 340 mg/m2) administered one week before chemoradiotherapy and repeated weekly up to six doses.
Trial: 27535748
Drug: Evofosfamide in
RxNorm normalized name: trofosfamide
DrugBank: Trofosfamide (DB12902)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evofosfamide in combination with neo-adjuvant chemoradiotherapy.
Trial: 27536421
Drug: Amlodipine/valsartan (A/V)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine/valsartan (A/V) 10/160 mg
Trial: 27536421
Drug: Losartan/hydrochlorothiazide (L/H)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan/hydrochlorothiazide (L/H) 100/25 mg
Trial: 27536422
Drug: Metformin for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin for 52 weeks (active control)
Trial: 27536436
Drug: Belimumab (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Belimumab (1 mg/kg and 10 mg/kg)
Trial: 27536442
Drug: Migalastat HCl
RxNorm normalized name: migalastat HCl
DrugBank: Migalastat (DB05018)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Migalastat HCl 50 mg
Trial: 27536442
Drug: Migalastat HCl
RxNorm normalized name: migalastat HCl
DrugBank: Migalastat (DB05018)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Migalastat HCl 150 mg
Trial: 27536442
Drug: Migalastat HCl
RxNorm normalized name: migalastat HCl
DrugBank: Migalastat (DB05018)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Migalastat HCl 450 mg
Trial: 27536449
Drug: Levomilnacipran ER
RxNorm normalized name: levomilnacipran Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levomilnacipran ER 40-120 mg/day
Trial: 27536452
Drug: Levocetirizine oral
RxNorm normalized name: levocetirizine Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levocetirizine oral solution (OS) 5 mg
Trial: 27536452
Drug: Cetirizine dry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetirizine dry syrup (DS) 10 mg
Trial: 27536459
Drug: 5 ×
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 × 0.1 mg dutasteride capsules
Trial: 27536459
Drug: 1 ×
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 × 0.5 mg dutasteride capsule
Trial: 27536708
Drug: Intrathecal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrathecal administration of rituximab
Trial: 27537786
Drug: Deferasirox (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deferasirox (up to 40 mg/kg/d)
Trial: 27538465
Drug: Panagen (tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Panagen (tablet form of fragmented human DNA preparation)
Trial: 27540019
Drug: High-dose inhaled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose inhaled corticosteroid (ICS) treatment
Trial: 27540019
Drug: High-dose ICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose ICS
Trial: 27544054
Drug: PRAME immunotherapeutic
RxNorm normalized name: PrameGel Reformulated Apr 2012
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRAME immunotherapeutic (20 μg)
Trial: 27544054
Drug: PRAME immunotherapeutic
RxNorm normalized name: PrameGel Reformulated Apr 2012
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRAME immunotherapeutic (100 μg)
Trial: 27544054
Drug: PRAME immunotherapeutic
RxNorm normalized name: PrameGel Reformulated Apr 2012
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRAME immunotherapeutic (500 μg)
Trial: 27544054
Drug: PRAME immunotherapeutic
RxNorm normalized name: PrameGel Reformulated Apr 2012
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRAME immunotherapeutic (all doses)
Trial: 27547173
Drug: Standard and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard and contingency management treatment
Trial: 27547422
Drug: Short-term intensive
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term intensive insulin therapy (IIT) for 2-4 weeks (basal detemir, bolus aspart) followed by placebo therapy for 48 weeks
Trial: 27547429
Drug: BQ-123 (selective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BQ-123 (selective endothelin A receptor antagonist)
Trial: 27550351
Drug: Ceftolozane-tazobactam 3
RxNorm normalized name: ceftolozane / tazobactam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftolozane-tazobactam 3 g every 8 hours (q8h)
Trial: 27551171
Drug: Acetaminophen plus
RxNorm normalized name: acetaminophen / hydrocodone Oral Capsule [Ceta Plus]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen plus 10 mg/day of native type II collagen (group AC+CII)
Trial: 27551171
Drug: 1500 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1500 mg/day of acetaminophen (group AC)
Trial: 27551317
Drug: Oxidized fish
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxidized fish oil (8 g daily, EPA+DHA 1.6 g)
Trial: 27551317
Drug: High-quality fish
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-quality fish oil (8 g daily, EPA+DHA 1.6 g)
Trial: 27552578
Drug: Vitamin K
RxNorm normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin K antagonist (VKA) treatment in Asia (1356 patients, 37.8%)
Trial: 27552578
Drug: Vitamin K
RxNorm normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin K antagonist (VKA) treatment in ORW (7081 patients, 53.3%)
Trial: 27554014
Drug: LNG IUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LNG IUS (levonorgestrel intrauterine system) 52 mg inserted at 2 weeks postpartum
Trial: 27554105
Drug: Contemporary treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contemporary treatment (pharmacological and invasive)
Trial: 27557643
Drug: Selinexor/doxorubicin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selinexor/doxorubicin treatment
Trial: 27557949
Drug: Antipsychotic-related dopamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotic-related dopamine D2/3 receptor occupancy
Trial: 27558181
Drug: Rifamycin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifamycin treatment
Trial: 27558635
Drug: 1 ×
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 × 10^6 CEA-pulsed DCs mixed with tetanus toxoid (adjuvant) and low-dose interleukin-2 administered subcutaneously after final DC vaccination.
Trial: 27560141
Drug: Family-based childhood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family-based childhood obesity treatment program
Trial: 27561167
Drug: Dual antiplatelet
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual antiplatelet therapy in PEGASUS-like population (Group 1)
Trial: 27561720
Drug: Clofarabine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clofarabine (30 mg/m²) and cytosine arabinoside followed by reduced-intensity conditioning before allogeneic stem-cell transplantation
Trial: 27561844
Drug: DEBIRI (drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DEBIRI (drug eluting PVA microspheres loaded with irinotecan)
Trial: 27561844
Drug: DEBIRI (median
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DEBIRI (median dose of 103 mg irinotecan)
Trial: 27565186
Drug: Self-reported medication
RxNorm normalized name: black imported fire ant allergenic extract
DrugBank: Solenopsis richteri (DB11026)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-reported medication intake and fall incidents via smartphone app
Trial: 27566701
Drug: LY3022856 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY3022856 at doses of 5-30 mg/kg weekly (qwk)
Trial: 27566701
Drug: LY3022856 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY3022856 at 30 mg/kg qwk in colorectal cancer patients
Trial: 27567500
Drug: Rifampin 20
RxNorm normalized name: rifampin 20 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampin 20 mg/kg/day
Trial: 27567500
Drug: Rifampin 15
RxNorm normalized name: rifampin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampin 15 mg/kg/day
Trial: 27567500
Drug: Rifampin 10
RxNorm normalized name: Rifampin
DrugBank: Rifampin (DB01045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampin 10 mg/kg/day (control)
Trial: 27568453
Drug: Anti-dementia drugs
RxNorm normalized name: ANTI-DEMENTIA DRUGS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-dementia drugs (acetylcholinesterase inhibitors and memantine)
Trial: 27568453
Drug: Control (patients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (patients with dementia who did not take anti-dementia drugs)
Trial: 27570087
Drug: Ofatumumab consolidation
RxNorm normalized name: Ofatumumab
DrugBank: Ofatumumab (DB06650)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ofatumumab consolidation (1000 mg once every 4 weeks)
Trial: 27570087
Drug: Ofatumumab induction
RxNorm normalized name: Ofatumumab
DrugBank: Ofatumumab (DB06650)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ofatumumab induction (300 mg on day 1 and 1000 mg on day 2; cycles 2-6: 1000 mg on day 1)
Trial: 27570245
Drug: Delafloxacin 300
RxNorm normalized name: delafloxacin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delafloxacin 300 mg intravenous
Trial: 27570807
Drug: IL-6 c.-174
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL-6 c.-174 CC genotype
Trial: 27572392
Drug: Meropenem 2
RxNorm normalized name: meropenem 2000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meropenem 2 g every 8 hours (q8h)
Trial: 27572392
Drug: Meropenem 1
RxNorm normalized name: meropenem 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meropenem 1 g every 8 hours (q8h)
Trial: 27572392
Drug: Meropenem 1
RxNorm normalized name: meropenem 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meropenem 1 g every 6 hours (q6h)
Trial: 30730782
Drug: Andexanet alfa
RxNorm normalized name: andexanet alfa
DrugBank: Andexanet alfa (DB14562)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Andexanet alfa (bolus followed by a 2-hour infusion)
Trial: 27573663
Drug: Vinblastine (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinblastine (6 mg/m2) administered once per week
Trial: 27575984
Drug: Instrumental Activities
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Instrumental Activities of Daily Living (IADL)
Trial: 27576691
Drug: EPI-002 (known
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPI-002 (known AR AF-1 inhibitor)
Trial: 27580835
Drug: Drug-eluting stent
RxNorm normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-eluting stent implantation
Trial: 27581438
Drug: 13-valent pneumococcal
RxNorm normalized name: Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine
DrugBank: Streptococcus pneumoniae type 14 capsular polysaccharide diphtheria CRM197 protein conjugate antigen (DB10289)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 13-valent pneumococcal conjugate vaccine (PCV13), single dose
Trial: 27581469
Drug: Pregnancy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregnancy with depleted iron stores (SF <12 μg/L)
Trial: 27581477
Drug: Maternal protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maternal protein intake during pregnancy (mean second-trimester protein intake: 1.4 g · kg)
Trial: 27582220
Drug: Aducanumab (human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aducanumab (human monoclonal antibody) administered via monthly intravenous infusions for one year
Trial: 27582480
Drug: Treatment program
RxNorm normalized name: ZO Skin Health Acne Prevention Plus Treatment Program KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment program for WTC dust exposure